Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan;
Anticancer Res. 2021 Dec;41(12):6225-6230. doi: 10.21873/anticanres.15442.
Hepatocellular carcinoma (HCC) occasionally presents with simultaneous or metachronous primary malignancies of other organs. Despite the limited scope of cytocidal anticancer drugs or molecular targeted agents, immune checkpoint inhibitors (ICIs) can still be used for various malignancies. Here, we present cases of double cancers including HCC treated with ICIs.
Case 1: A 70-year-old man with lung cancer and 80-mm HCC underwent nivolumab therapy. The sizes of both cancers remained constant for nine months. Case 2: A 58-year-old man with pharyngeal cancer and HCC. Nivolumab was administered, but was withdrawn after one session because of progressive disease. Case 3: A 71-year-old man with a 5 cm HCC invading the inferior vena cava, and early esophageal cancer. HCC showed a significant volume reduction and esophageal cancer demonstrated slight improvement by atezolizumab and bevacizumab therapy.
A combination therapy including ICI is a promising treatment option for HCC with concurrent malignancies.
肝细胞癌（HCC）偶尔会同时或异时出现其他器官的原发性恶性肿瘤。尽管细胞毒性抗癌药物或分子靶向药物的范围有限，但免疫检查点抑制剂（ICI）仍可用于各种恶性肿瘤。在这里，我们介绍了包括 HCC 在内的双重癌症病例，这些病例接受了 ICI 治疗。
病例 1：一名 70 岁男性患有肺癌和 80mm HCC，接受了nivolumab 治疗。九个月来，两种癌症的大小都保持不变。病例 2：一名 58 岁男性患有鼻咽癌和 HCC。给予nivolumab，但由于疾病进展，在一个疗程后停药。病例 3：一名 71 岁男性患有 5cm HCC 侵犯下腔静脉和早期食管癌。HCC 显示出明显的体积缩小，而atezolizumab 和 bevacizumab 治疗使食管癌略有改善。
ICI 联合治疗是 HCC 合并恶性肿瘤的一种有前途的治疗选择。
